Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life-threatening diseases. The company is headquartered in Hayward, California and currently employs 21 full-time employees. The company went IPO on 2010-03-02. The firm has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.
Follow-Up Questions
Qui est le CEO de Anthera Pharmaceuticals Inc ?
Mr. J. Craig Thompson est le President de Anthera Pharmaceuticals Inc, il a rejoint l'entreprise depuis 2016.
Quelle est la performance du prix de l'action ANTH ?
Le prix actuel de ANTH est de $0.0001, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Anthera Pharmaceuticals Inc ?
Anthera Pharmaceuticals Inc appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Anthera Pharmaceuticals Inc ?
La capitalisation boursière actuelle de Anthera Pharmaceuticals Inc est de $2618
